Table 4.
Potential treatment targets for gastrointestinal stromal tumors
| Category | Name | ClinicalTrials.gov Identifier |
| TKI of KIT and PDGFRA | Masitinib (AB1010) | NCT00998751 (U)[57] |
| Crenolanib (CP-868,596) | NCT02847429 (R), NCT01243346 (C)[58] | |
| AZD2171 | NCT00385203 (C)[59] | |
| Vatalanib (PTK787) | NCT00117299 (C), NCT00655655 (A) | |
| OSI-930 | NCT00513851 (C) | |
| TKI258 | NCT01478373 (C), NCT01440959 (C) | |
| DCC-2618 | NCT02571036 (R) | |
| Biologic inhibitors of KIT and PDGFRA | Olaratumab (IMC-3G3) | NCT01316263 (C) |
| HSP90 inhibitors | Retaspimycin (IPI-5040) | NCT00276302 (C), NCT00688766 (T) |
| BIIB021 (CNF2024) | NCT00618319 (C) | |
| Ganetespib (STA-9090) | NCT01039519 (C) | |
| AUY922 | NCT01389583 (R), NCT01404650 (C) | |
| AT13387 | NCT01294202 (C) | |
| Inhibitors of pathways downstream of KIT and PDGFRA | RAS/RAF/MEK/ERK/MAPK inhibitors: MEK162 | NCT01991379 |
| AKT inhibitors: perifosine | NCT00455559 (C)[60] | |
| mTOR inhibitors: everolimus (RAD001) | NCT01275222 (C), NCT00510354 (C), NCT02071862 (R) | |
| mTOR inhibitors: temsirolimus (Torisel) | NCT00700258 (R) | |
| Cell cycle inhibitors | Alvocidib (Flavopiridol) | NCT00098579 (C) |
| Insulin-like growth factor pathway inhibitors | OSI-906 | NCT01560260 (C)[61] |
R: Recruiting; T: Terminated; C: Completed; A: Active, not recruiting; U: Unknown. PDGFRA: Platelet-derived growth factor receptor alpha.